Rubicon Limited RBC
Rubicon's NZ-listed holdco structure hides two world-class US assets — ArborGen and Tenon — that a Tenon auction, ArborGen NASDAQ relisting, and three new shareholder directors can unlock for 200-300%+ upside.
Thesis
Rubicon is a NZX-listed holding company owning 33% of ArborGen — one of the only global biotech tree-seedling players, alongside MeadWestvaco and International Paper — and 58% of Tenon, a vertically-integrated US building-products distributor with a Lowe's relationship. Sandell, a 10-year shareholder with a 14.4% stake, argues the 66% YTD share-price collapse reflects board-level mismanagement of the withdrawn ArborGen IPO and of Tenon expectations, not operational deterioration. A sum-of-parts (DCF on ArborGen, EBITDA multiple on Tenon) yields NZD 1.20 per share normalized and NZD 1.65 in a strategic sale — roughly 200-300% above the market price. Sandell urges the board to sell Rubicon outright or, alternatively, auction Tenon and reverse-merge ArborGen onto NASDAQ, and to add three shareholder representatives to restore accountability.
SCQA
Rubicon is a NZX-listed holding company whose only assets are a 33% stake in private biotech-seedlings leader ArborGen and a 58% stake in US building-products distributor Tenon.
The stock has collapsed 66% YTD — worst in the NZX All-Index — despite no operational deterioration; Sandell blames board mismanagement of the withdrawn ArborGen IPO and of Tenon expectations.
The board should urgently explore a sale of Rubicon, or auction Tenon and reverse-merge ArborGen onto NASDAQ, and expand itself with three shareholder representatives.
Sum-of-parts valuation yields NZD 1.20 per share on a normalized basis (~200% upside) and NZD 1.65 in a strategic sale scenario (~313% upside) from the current market price.
The three reasons
- 1
RBC trades at ~NZD 0.40 vs NZD 1.20-1.65 sum-of-parts — 200-300%+ upside
- 2
Shares down 66% YTD despite no deterioration in ArborGen or Tenon operations
- 3
Holding-company structure orphans US assets on the NZX with no sell-side coverage
Primary demands
- Sell Rubicon in its entirety to a strategic buyer
- Separate ArborGen by selling the 58% Tenon stake via auction and re-listing ArborGen on NASDAQ
- Expand the Board by adding three shareholder representatives
KPIs cited
Pattern membership
Where this document fits across the library's 12 rhetorical / structural patterns.
Precedents cited
- Monsanto (as analogue for ArborGen's biotech potential)
Notable slides (6)
Notes
Sandell Asset Management / Castlerigg Investments campaign targeting NZX-listed holdco Rubicon, owner of private US biotech-seedlings firm ArborGen and controlling stake in NZ-listed Tenon. Classic holdco-discount/sum-of-parts argument (NZD 1.20 normalized, NZD 1.65 strategic vs market ~NZD 0.40). Board is criticized collectively for the ArborGen IPO withdrawal and Tenon mismanagement, but no individual directors or executives are named as villains. Document has no signature block; author attributed to 'SAMC' as firm. Structure: Exec Summary (pp.2-4), Rubicon holdco (pp.5-8), ArborGen (pp.9-11), Tenon (pp.12-14). Page 15 not sampled but likely closing / back cover.